Acute Pain - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Acute Pain - Pipeline Review, H2 2016

Acute Pain - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Acute Pain - Pipeline Review, H2 2016
Published Aug 10, 2016
194 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Acute Pain - Pipeline Review, H2 2016, provides an overview of the Acute Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Pain and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Pain
- The report reviews pipeline therapeutics for Acute Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Pain therapeutics and enlists all their major and minor projects
- The report assesses Acute Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing stra

  
Source:
Document ID
GMDHC8346IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents210
  List of Tables101
  List of Figures111
Introduction121
  Global Markets Direct Report Coverage121
Acute Pain Overview131
Therapeutics Development142
  Pipeline Products for Acute Pain Overview141
  Pipeline Products for Acute Pain Comparative Analysis151
Acute Pain Therapeutics under Development by Companies164
Acute Pain Therapeutics under Investigation by Universities/Institutes201
Acute Pain Pipeline Products Glance214
  Late Stage Products211
  Clinical Stage Products221
  Early Stage Products231
  Unknown Stage Products241
Acute Pain Products under Development by Companies254
Acute Pain Products under Investigation by Universities/Institutes291
Acute Pain Companies Involved in Therapeutics Development3035
  AcelRx Pharmaceuticals, Inc.301
  Adynxx, Inc.311
  Amorsa Therapeutics Inc.321
  AnaBios Corporation331
  Anavex Life Sciences Corp.341
  AngioChem Inc.351
  Antibe Therapeutics, Inc.361
  AskAt Inc.371
  Cara Therapeutics, Inc.381
  Centrexion Therapeutics Corp391
  Charleston Laboratories, Inc.401
  ChironWells GmbH411
  Crescita Therapeutics Inc.421
  Cytogel Pharma, LLC431
  Dompe Farmaceutici S.p.A.441
  Grunenthal GmbH451
  Iroko Pharmaceuticals, LLC461
  KemPharm, Inc.471
  KPI Therapeutics, Inc.481
  Laboratorios Del Dr. Esteve S.A.491
  Mallinckrodt Plc501
  Nanomerics Ltd511
  Nanotherapeutics, Inc.521
  Orbis Biosciences Inc531
  Orexo AB541
  Orion Oyj551
  Pacira Pharmaceuticals, Inc.561
  Phosphagenics Limited571
  Recro Pharma, Inc.581
  Scilex Pharmaceuticals, Inc.591
  Shulov Innovative Science Ltd.601
  Syntrix Biosystems, Inc.611
  Thar Pharmaceuticals, Inc.621
  Trevena, Inc.631
  Yungjin Pharm. Co., Ltd.641
Acute Pain Therapeutics Assessment6512
  Assessment by Monotherapy Products651
  Assessment by Combination Products661
  Assessment by Target673
  Assessment by Mechanism of Action703
  Assessment by Route of Administration732
  Assessment by Molecule Type752
Drug Profiles7796
  (acetaminophen + benzhydrocodone hydrochloride) IR Drug Profile776
  (acetaminophen + hydrocodone bitartarate) ER Drug Profile832
  (acetaminophen + tramadol hydrochloride) SR Drug Profile851
  (buprenorphine hydrochloride + naloxone hydrochloride) Drug Profile861
  (celecoxib + tramadol hydrochloride) Drug Profile872
  AAT-076 Drug Profile891
  alfentanil hydrochloride Drug Profile901
  AMS-410 FA Drug Profile911
  ANAVEX-1037 Drug Profile921
  ANAVEX-1066 Drug Profile931
  ANAVEX-1067 Drug Profile941
  ANAVEX-1079 Drug Profile951
  ANAVEX-1519 Drug Profile961
  ANG-2002 Drug Profile971
  ARX-04 Drug Profile985
  ATB-352 Drug Profile1031
  AYX-1 Drug Profile1042
  BBI-11008 Drug Profile1061
  celecoxib Drug Profile1071
  CL-108 Drug Profile1082
  CR-4056 Drug Profile1101
  Cyt-1010 Drug Profile1112
  dexmedetomidine hydrochloride Drug Profile1133
  DF-2593A Drug Profile1161
  difelikefalin Drug Profile1178
  Drug for Acute Pain Drug Profile1251
  ECP-1014 Drug Profile1261
  ET-1 Drug Profile1271
  FY-101C Drug Profile1281
  FY-103B Drug Profile1291
  grapiprant Drug Profile1302
  HPI-201 Drug Profile1321
  HS-731 Drug Profile1331
  ibuprofen Drug Profile1341
  ibuprofen Drug Profile1351
  ibuprofen Drug Profile1361
  ketamine hydrochloride Drug Profile1372
  lidocaine hydrochloride Drug Profile1391
  meloxicam Drug Profile1403
  meloxicam Drug Profile1431
  meloxicam ER Drug Profile1441
  Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain Drug Profile1451
  MR-309 Drug Profile1462
  NM-0127 Drug Profile1481
  oliceridine Drug Profile1495
  Omnitram Drug Profile1541
  Peptides to Target TRPV1 for Pain and Itch Drug Profile1551
  prednisone Drug Profile1561
  Prostatic Acid Phosphatase Drug Profile1571
  RO-656570 Drug Profile1581
  Small Molecule to Block Nav1.9 Channel for Pain Drug Profile1591
  Small Molecules to Block Nav 1.7 for Pain Drug Profile1601
  Small Molecules to Block Nav 1.8 for Pain Drug Profile1611
  Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain Drug Profile1621
  T-109 Drug Profile1631
  tapentadol hydrochloride Drug Profile1642
  TRV-734 Drug Profile1662
  U-2902 Drug Profile1682
  VPX-595 Drug Profile1701
  ZEP-3 Drug Profile1712
Acute Pain Dormant Projects1737
Acute Pain Discontinued Products1802
Acute Pain Product Development Milestones18211
  Featured News &Press Releases1821
    Jul 26, 2016: Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam1821
    Jun 28, 2016: AcelRx Pharmaceuticals Completes Patient Enrollment in Remaining Phase 3 Studies of ARX-04 as a Potential Treatment of Moderate-to-Severe Acute Pain1831
    Jun 13, 2016: Charleston Laboratories and Daiichi Sankyo Announce FDA Acceptance of New Drug Application for CL-1081831
    Jun 09, 2016: Cara Therapeutics to Present Preclinical Data at June Medical Meetings1841
    Jun 08, 2016: Trevena Announces First Patients Enrolled in the APOLLO-1 and APOLLO-2 Phase 3 Pivotal Efficacy Studies of Oliceridine in Acute Pain1851
    May 26, 2016: AcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX-04 following Ambulatory Abdominal Surgeries at Euroanaesthesia1851
    May 24, 2016: New Study Reveals Cost of Initial IV Opioid Dose in the Emergency Department for the Treatment of Acute Pain Exceeds $1401861
    May 12, 2016: Recro Pharma Presents Clinical Data at American Pain Society 35th Annual Scientific Meeting1871
    May 06, 2016: AcelRx Pharmaceuticals Presents Subgroup Analysis Demonstrating Positive Results of ARX-04 by Type of Abdominal Surgery1871
    May 02, 2016: Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine1881
    Mar 14, 2016: AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study1891
    Mar 07, 2016: AcelRx Pharmaceuticals Initiates Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain1901
    Feb 25, 2016: AcelRx Pharmaceuticals Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores in ER Patients in Interim Phase 3 Analysis1901
    Feb 22, 2016: Trevena Receives FDA Breakthrough Therapy Designation for Oliceridine1911
    Feb 18, 2016: Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine 32nd Annual Meeting1912
Appendix1932
  Methodology1931
  Coverage1931
  Secondary Research1931
  Primary Research1931
  Expert Panel Validation1931
  Contact Us1931
  Disclaimer1941

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Acute Pain - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Acute-Pain-Pipeline-Review-H2-2016-2088-16354>
  
APA:
Global Markets Direct - Market Research. (2016). Acute Pain - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Acute-Pain-Pipeline-Review-H2-2016-2088-16354>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.